Details for New Drug Application (NDA): 022224
✉ Email this page to a colleague
The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.
Summary for 022224
Tradename: | TRILIPIX |
Applicant: | Abbvie |
Ingredient: | choline fenofibrate |
Patents: | 1 |
Suppliers and Packaging for NDA: 022224
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TRILIPIX | choline fenofibrate | CAPSULE, DELAYED RELEASE;ORAL | 022224 | NDA | AbbVie Inc. | 0074-3161 | 0074-3161-90 | 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0074-3161-90) |
TRILIPIX | choline fenofibrate | CAPSULE, DELAYED RELEASE;ORAL | 022224 | NDA | AbbVie Inc. | 0074-3162 | 0074-3162-90 | 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0074-3162-90) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, DELAYED RELEASE;ORAL | Strength | EQ 45MG FENOFIBRIC ACID | ||||
Approval Date: | Dec 15, 2008 | TE: | AB | RLD: | Yes | ||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 7, 2025 | Product Flag? | Substance Flag? | Y | Delist Request? |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, DELAYED RELEASE;ORAL | Strength | EQ 135MG FENOFIBRIC ACID | ||||
Approval Date: | Dec 15, 2008 | TE: | AB | RLD: | Yes | ||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 7, 2025 | Product Flag? | Substance Flag? | Y | Delist Request? |
Complete Access Available with Subscription